|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DCAF12 |
Gene summary for DCAF12 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DCAF12 | Gene ID | 25853 |
| Gene name | DDB1 and CUL4 associated factor 12 | |
| Gene Alias | CT102 | |
| Cytomap | 9p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q5T6F0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 25853 | DCAF12 | LZE4T | Human | Esophagus | ESCC | 2.72e-09 | 3.28e-01 | 0.0811 |
| 25853 | DCAF12 | LZE8T | Human | Esophagus | ESCC | 8.82e-05 | 2.03e-01 | 0.067 |
| 25853 | DCAF12 | LZE20T | Human | Esophagus | ESCC | 1.03e-04 | 4.31e-02 | 0.0662 |
| 25853 | DCAF12 | LZE24T | Human | Esophagus | ESCC | 3.94e-19 | 5.44e-01 | 0.0596 |
| 25853 | DCAF12 | LZE6T | Human | Esophagus | ESCC | 1.16e-02 | 1.57e-01 | 0.0845 |
| 25853 | DCAF12 | P1T-E | Human | Esophagus | ESCC | 1.40e-03 | 2.11e-01 | 0.0875 |
| 25853 | DCAF12 | P2T-E | Human | Esophagus | ESCC | 1.16e-32 | 6.35e-01 | 0.1177 |
| 25853 | DCAF12 | P4T-E | Human | Esophagus | ESCC | 6.95e-13 | 1.86e-01 | 0.1323 |
| 25853 | DCAF12 | P5T-E | Human | Esophagus | ESCC | 3.06e-12 | 2.76e-01 | 0.1327 |
| 25853 | DCAF12 | P8T-E | Human | Esophagus | ESCC | 2.81e-20 | 1.90e-01 | 0.0889 |
| 25853 | DCAF12 | P9T-E | Human | Esophagus | ESCC | 3.52e-19 | 5.43e-01 | 0.1131 |
| 25853 | DCAF12 | P10T-E | Human | Esophagus | ESCC | 3.90e-21 | 3.09e-01 | 0.116 |
| 25853 | DCAF12 | P11T-E | Human | Esophagus | ESCC | 6.68e-10 | 4.08e-01 | 0.1426 |
| 25853 | DCAF12 | P12T-E | Human | Esophagus | ESCC | 2.39e-21 | 2.71e-01 | 0.1122 |
| 25853 | DCAF12 | P15T-E | Human | Esophagus | ESCC | 2.61e-18 | 3.54e-01 | 0.1149 |
| 25853 | DCAF12 | P16T-E | Human | Esophagus | ESCC | 3.00e-19 | 3.12e-01 | 0.1153 |
| 25853 | DCAF12 | P17T-E | Human | Esophagus | ESCC | 1.77e-04 | 3.15e-01 | 0.1278 |
| 25853 | DCAF12 | P19T-E | Human | Esophagus | ESCC | 5.06e-07 | 5.67e-01 | 0.1662 |
| 25853 | DCAF12 | P20T-E | Human | Esophagus | ESCC | 5.36e-12 | 1.65e-01 | 0.1124 |
| 25853 | DCAF12 | P21T-E | Human | Esophagus | ESCC | 1.20e-23 | 3.31e-01 | 0.1617 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
| GO:0043161111 | Esophagus | ESCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 312/8552 | 412/18723 | 3.53e-36 | 4.48e-33 | 312 |
| GO:001050617 | Esophagus | ESCC | regulation of autophagy | 220/8552 | 317/18723 | 6.72e-18 | 6.36e-16 | 220 |
| GO:001049812 | Liver | Cirrhotic | proteasomal protein catabolic process | 216/4634 | 490/18723 | 2.52e-21 | 9.29e-19 | 216 |
| GO:004316112 | Liver | Cirrhotic | proteasome-mediated ubiquitin-dependent protein catabolic process | 184/4634 | 412/18723 | 4.52e-19 | 8.85e-17 | 184 |
| GO:001050611 | Liver | Cirrhotic | regulation of autophagy | 132/4634 | 317/18723 | 2.17e-11 | 1.33e-09 | 132 |
| GO:001049822 | Liver | HCC | proteasomal protein catabolic process | 351/7958 | 490/18723 | 6.92e-40 | 1.46e-36 | 351 |
| GO:004316122 | Liver | HCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 299/7958 | 412/18723 | 7.82e-36 | 8.27e-33 | 299 |
| GO:001050621 | Liver | HCC | regulation of autophagy | 210/7958 | 317/18723 | 7.59e-18 | 8.45e-16 | 210 |
| GO:001049820 | Oral cavity | OSCC | proteasomal protein catabolic process | 336/7305 | 490/18723 | 5.45e-41 | 8.63e-38 | 336 |
| GO:004316120 | Oral cavity | OSCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 285/7305 | 412/18723 | 5.68e-36 | 5.99e-33 | 285 |
| GO:001050610 | Oral cavity | OSCC | regulation of autophagy | 198/7305 | 317/18723 | 1.63e-17 | 1.51e-15 | 198 |
| GO:0010498110 | Oral cavity | LP | proteasomal protein catabolic process | 224/4623 | 490/18723 | 9.57e-25 | 4.00e-22 | 224 |
| GO:0043161110 | Oral cavity | LP | proteasome-mediated ubiquitin-dependent protein catabolic process | 190/4623 | 412/18723 | 1.08e-21 | 2.93e-19 | 190 |
| GO:001050615 | Oral cavity | LP | regulation of autophagy | 132/4623 | 317/18723 | 1.82e-11 | 1.28e-09 | 132 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DCAF12 | SNV | Missense_Mutation | novel | c.883N>C | p.Tyr295His | p.Y295H | Q5T6F0 | protein_coding | tolerated(0.18) | benign(0.086) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DCAF12 | SNV | Missense_Mutation | c.122N>T | p.Pro41Leu | p.P41L | Q5T6F0 | protein_coding | tolerated(0.18) | benign(0.048) | TCGA-AO-A12D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| DCAF12 | SNV | Missense_Mutation | c.455G>C | p.Arg152Thr | p.R152T | Q5T6F0 | protein_coding | deleterious(0.02) | benign(0.201) | TCGA-E2-A14R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD | |
| DCAF12 | insertion | Nonsense_Mutation | novel | c.421_422insAAAGCCCCTGTCCTCTTGAAGCCTACATTCTAGTGGA | p.Cys141Ter | p.C141* | Q5T6F0 | protein_coding | TCGA-A8-A06U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| DCAF12 | deletion | Frame_Shift_Del | novel | c.1081delT | p.Ser361ProfsTer27 | p.S361Pfs*27 | Q5T6F0 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| DCAF12 | SNV | Missense_Mutation | novel | c.547N>T | p.His183Tyr | p.H183Y | Q5T6F0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| DCAF12 | SNV | Missense_Mutation | rs761820325 | c.506N>A | p.Arg169Gln | p.R169Q | Q5T6F0 | protein_coding | tolerated(1) | benign(0.001) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| DCAF12 | SNV | Missense_Mutation | novel | c.775G>A | p.Ala259Thr | p.A259T | Q5T6F0 | protein_coding | deleterious(0.03) | possibly_damaging(0.685) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DCAF12 | SNV | Missense_Mutation | c.131G>A | p.Arg44Lys | p.R44K | Q5T6F0 | protein_coding | tolerated(0.13) | benign(0.01) | TCGA-AD-6899-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| DCAF12 | SNV | Missense_Mutation | c.846N>C | p.Glu282Asp | p.E282D | Q5T6F0 | protein_coding | deleterious(0.05) | benign(0.4) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |